Cailian News reporters learned at the 2024 medical insurance catalog negotiation/auction site that this afternoon's negotiation drugs include multiple psychiatric drugs and orphan drugs. Jiangsu Hengrui Pharmaceuticals' Fumarsan Taigilideng Injection, Otokanko Capsules, Humanwell Healthcare's Hydrocodone Slow-release Tablets and Lorazepam Tablets, Bio-Thera Solutions' Cetuximab Injection, Yunding New Glory's Budesonide Enteric Capsules, as well as the overseas company Sanofi's Rosuvastatin Ezetimibe Tablets (I), and Novartis' Enixolan Sodium Injection are all part of the afternoon negotiation plan. About an hour after the afternoon session started, the first group of representatives appeared, and the subsequent negotiation progress of corporate representatives seemed slow. Up to now, the corporate representatives who have appeared are relatively silent and unwilling to engage in too much conversation. (Cailian News reporters He Fan Lu A Feng).